



State of The Art Technology  
Cost-Effective Service  
CMO/CDMO/CRO  
In/Out Licensing  
API/FDF/Biosimilar



# Taiwan

Pharmaceutical Alliance

臺灣醫藥品聯盟



Industrial Development Administration  
MOEA



Medical and Pharmaceutical Industry  
Technology and Development Center

## About TPA

Taiwan Pharmaceutical Alliance (TPA) is comprised of the top Taiwanese pharmaceutical companies and was established by the Medical and Pharmaceutical Industry Technology and Development Center (PITDC) that is under the Industrial Development Administration (IDA) as a part of the Ministry of Economic Affairs.

There are 16 members in the TPA currently. We have a collection of APIs, niche generics, 505(b)(2)s, biosimilars, and medical supplies. Almost all the therapeutic areas are covered by TPA while each member has their own expertise. The finished formulations contain various types of oral forms, semi-solids, injectables, eye drops, MDIs/DPIs/nasal sprays, patches, topicals, etc.

TPA also provides CMO/CDMO services. Just like any Taiwanese manufacturing facility, TPA members are PIC/S GMP accredited, most are certified by US FDA, EU EMA, and Japan PMDA. TPA's presence is throughout the world in many regions, such as the US, Europe, MENA, Japan, and ASEAN. Our high-quality products have been recognized by many international partners.

The vision of TPA is to collaborate with the global pharmaceutical community and to solid business partnership. We are committed to bringing the best quality of medicine to patients and to fulfilling the global unmet medical needs.

台湾医薬品連盟は、台湾国内の製薬会社の専門、イノベーション及びサービス精神をひとつにし、国際市場を共同開発することを目的として台湾經濟部産業發展署が財団法人医薬工業技術發展センターを通じて、「製薬工業技術普及促進及び補導計画」に基づき設立されました。当連盟には、16の製薬企業が加盟しております。これら全ての加盟企業の製造工場が台湾衛生当局により、PIC/S GMPの適合工場として認証されております。

また、各加盟企業は台湾政府による指導のもと、製造技術及び品質向上に努め、欧州、米国、日本の求める水準に達しております。台湾のイメージアップと共に台湾企業と海外企業の国際経済交流を強化するため、台湾政府は当連盟を成立させ、世界に誇る数々の台湾の製薬会社を国際市場にアピールしたいと考えております。台湾医薬品連盟は、政府と同じ理念を持ち、台湾製薬業界の発展に尽力しております。



### Therapeutic Areas

- Antibiotics
- Cardiovascular
- Central Nervous System
- Diabetes
- External Use
- Gastrointestinal
- Genitourinary
- Hormone
- Immunology/Rheumatology
- Musculoskeletal
- Oncology
- Ophthalmology
- Others
- Psychiatry
- Respiratory
- Supplement
- Vitamins



### Product

- Active Pharmaceutical Ingredients
- Finished Dosage Forms
- Traditional Chinese Medicine
- Medical Supplies (Rubber Stoppers)



















### Services

- Contract Manufacturing
- Contract Development and Manufacturing
- R&D Services
- In/Out Licensing
- Contract Research



# Dosage Form

			Dosage Forms														More Options	
Company Name	Abbrev.	Sterile - Liquid	Sterile - Semi-solid	Sterile - Solid	Liquid	Semi-solid	Solid	Patches	Aerosols	Biologics	API	Penicillins	Cephalosporins	Hormones	Cytotoxics	Dietary Supplement	Packaging Materials	CRO Services
 China Chemical & Pharmaceutical Co. Ltd.	CCPC	●				●	●				●	●	●					
 Chung Mei Biopharma Co. Ltd.	CMB				●	●	●									●		
 Mithra Biotechnology Inc.	Mithra																	●
 Pei Li Pharmaceutical Industrial Co., Ltd.	Pei Li					●	●							●				
 Prince Pharmaceutical Co., Ltd.	Prince										●					●		
 Savior Lifetec Corporation	SLC			●							●							●
 Sinphar Pharmaceutical Co. Ltd.	Sinphar	●	●		●	●	●				●			●	●	●	●	●
 Standard Chem. & Pharm. Co., Ltd.	SCP	●			●	●	●						●					
 Sunny Pharmtech Inc.	Sunny	●		●	●		●				●				●			
 Swiss Pharmaceutical Co., Ltd.	Swiss	●			●	●	●						●			●		
 Synmosa Biopharma Corporation	Synmosa				●	●	●		●		●			●		●		
 Syn-Tech Chem. & Pharm. Co., Ltd.	Syn-Tech										●							
 Taiwan Biotech Co., Ltd.	TBC	●			●		●	●	●		●	●	●			●		
 Taiwan Tasheh Biotech Co., Ltd.	SZ																●	
 UBI Pharma Inc.	UBIP	●		●	●	●	●			●								●
 Yuanzhou Pharma	YCP				●	●	●											



## Alliance Members

State of The Art Technology  
Cost-Effective Service  
CMO/CDMO/CRO  
In/Out Licensing  
API/FDF/Biosimilar

China Chemical & Pharmaceutical Co. Ltd. 7

8 Chung Mei Biopharma Co. Ltd.

Mithra Biotechnology Inc. 9

10 Pei Li Pharmaceutical Industrial Co.,Ltd.

Prince Pharmaceutical Co., Ltd. 11

12 Savior Lifetec Corporation

Sinphar Pharmaceutical Co. Ltd. 13

14 Standard Chem. & Pharm. Co., Ltd.

Sunny Pharmtech Inc. 15

16 Swiss Pharmaceutical Co., Ltd.

Synmosa Biopharma Corporation 17

18 Syn-Tech Chem.& Pharm. Co., Ltd.

Taiwan Biotech Co., Ltd. 19

20 Taiwan Tasheh Biotech Co.,Ltd.

UBI Pharma Inc. 21

22 Yuanchou Pharma



中國化學製藥股份有限公司  
China Chemical & Pharmaceutical Co. Ltd.

[www.ccpq.com.tw/index\\_en.aspx](http://www.ccpq.com.tw/index_en.aspx)

Services: CMO, CDMO

Therapeutic Area:

1. Anti-Infections
2. Respiratory System
3. Immunosuppressant
4. Hematology/Oncology
5. Circulatory System

Dosage Forms:

1. Osmotic Controlled Release Oral Delivery System (OROS)
2. Repeated-Release System
3. Multiple-Layered Tablet
4. Multiple-Unit Pellet System
5. Solid Dispersion System
6. Pre-Filled Syringe

#### Brief Introduction:

Founded in 1952, China Chemical & Pharmaceutical Co., Ltd. (CCPC) is dedicated to the innovation, R&D, manufacturing, and service and quality improvement. Currently, CCPC provides more than 430 pharmaceutical products for both human and animal uses as well as healthcare products for humans. The scope of services ranges from CMO/CDMO services of pharmaceutical and healthcare products, R&D services, household products and beauty cosmetics marketing, and home care services. Since established, CCPC has a long and well reputed record of collaboration with worldwide partners in supplying products from PIC/S GMP, Japan PMDA, US FDA certified facilities. CCPC strategizes in vertical integration of its affiliates to focus on the development of APIs and generic drugs to target global markets. We hold an exceptional R&D team with unique technology platforms in Taiwan in creating product competitive advantages for our global partners; thus broadening CCPC's collaboration opportunities and enhancing brand image internationally.

中國化工製藥 (CCPC) は1952年に設立されて、イノベーション、研究開発、製造、サービスと品質の向上に注力しております。ヒトと動物向けの医薬品を430品目を超える製品を提供しています。提供可能なサービスは、医薬品及びヘルスケア製品のCMO/CDMO、研究開発、家庭用品及び美容化粧品のマーケティング、ホームケアサービスまで幅広くしております。CCPCは設立以来、PIC/S GMP、PMDA、USFDAの承認を得て、製品を供給し、世界中のパートナーと協力してきた長く評判の高い実績を持っております。CCPCは、世界市場をターゲットとしたAPI及びジェネリック医薬品の開発に重点を置くために、関連会社の垂直統合における戦略を立てております。また、当社は、台湾に独自の技術プラットフォームを備えた卓越した研究開発チームを擁し、グローバルパートナー向けに製品競争力の優位性を生み出しています。これにより、CCPCは広い分野でのコラボレーションの機会が広がり、国際的なブランドイメージが向上します。

#### Highlights of the Year:

Tacrolimus ER capsules – Pilot BE on-going



中美生技醫藥股份有限公司  
Chung Mei Biopharma Co. LTD.

[www.cm-biopharma.com/](http://www.cm-biopharma.com/)

Services: CMO, CDMO

Therapeutic Area:  
OTC Drug

Dosage Forms:

1. Oral Liquid Preparation: Syrup, Solution, Emulsion, Suspension
2. Solid Preparation: Lozenge, Film-Coated Tablet, Capsule, Granule, Tablet, and Pellet
3. External Liquid

#### Brief Introduction:

Embodying the principle that the essence of medicine is morality, pharmaceuticals serve the public good. Chung Mei Pharma Group established "Chung Mei Biopharma" in 2014. Founded in 1936, Chung Mei Pharmaceutical Co., Ltd. (CM) is primarily focused on over-the-counter pharmaceuticals. Over eight decades, we have relentlessly cooperated with leading pharmaceutical companies, research centers and biotech centers from the local level to the global level. We are committed to the full integration of cutting-edge manufacturing techniques and new concepts through continuous research and development. Chung Mei provides services from professional manufacturing to end-user sales (OEM & ODM), and integrates the biotech medical supply and distribution chains. We can produce oral liquid preparation (syrup, solution, emulsion, suspension); solid preparation (lozenge, film-coated tablet, capsule, granule, tablet, and pellet); external liquid and health food (tablet, capsule, powder, granule, etc.). We have also passed the high standards of cGMP, PIC/S GMP, ISO 22000 and Halal certifications. We expect to bring Taiwan's high-quality medicine to the Chinese and Asian markets. We aim to make the 'Made in Taiwan' brand a source of pride for everyone in Taiwan.

医薬品は倫理的なビジネスであり、私たちはすべての命を大切にします。中美エンタープライズグループは、2014年に「中美バイオファーマ」を設立しました。1936年に始まり、中美兄弟製薬株式会社 (CM) は主に一般用医薬品に焦点を当てています。85年間、私たちは国内外の先導的な製薬会社、研究センター、バイオテックセンターと絶えず協力してきました。私たちは、継続的な研究開発を通じて最新の製造技術を完全に統合し、新しい概念を推進することに尽力しています。中美は、専門的な製造からエンドユーザーへの販売 (OEM および ODM) までをサービスし、バイオテクノロジー医療用品および販売チェーンを統合しています。私たちは、口服液剤 (シロップ、溶液、乳剤、懸濁液)、固形剤 (トローチ、フィルムコーティング錠、顆粒、錠剤、カプセル、ペレット)、外用液剤、健康食品 (錠剤、カプセル、パウダー、顆粒など) を生産できます。また、cGMP、PIC/S GMP、ISO 22000、ハラル認証の高い基準をクリアしています。私たちは、台湾の高品質な医薬品を中国およびアジア市場に導入し、すべての台湾人が「MIT」マークを誇りに思うことを期待しています。

#### Highlights of the Year:

1. Benzydamine Hydrochloride-Spray 28ml/32ml 1.5mg
2. Benzydamine Hydrochloride-Spray 28ml 3.0mg
3. Amorolfine HCL-Lacquer 3.0ml 55.74mg





明生生物科技股份有限公司  
Mithra Biotechnology Inc.

www.mithracro.com

Services: Laboratory Services & Clinical Trials

- 1. Bioequivalence Study
- 2. Clinical Research
- 3. Biopharmaceutical Analysis
- 4. Bioanalysis
- 5. Pharmaceutical Analysis

- Specialty:
- 1. NCE
  - 2. Generics
  - 3. Biologics
  - 4. Biosimilars
  - 5. ADCs

#### Brief Introduction:


Mithra Biotechnology Inc., the first Contract Research Organization (CRO) in Taiwan since 1988, offers integrated and multi-dimensional CRO services including bioanalytical services for chemical drugs and biologics, full characterization plans for biologics, bioavailability/bioequivalence (BA/BE) studies, and early phase clinical trials to facilitate pharmaceutical development. With profound expertise in biological products diverse in monoclonal antibodies, growth factors, antibody drug conjugates (ADC) and other various proteins, the company's services include primary structure characterization, PTMs identification, disulfide bond assignment, carbohydrate structure analysis, variants analysis and peptide mapping for biosimilar comparison or lot-to-lot QC, and degradation/impurities profiling.

The company has proven expertise and experience in meeting international standards to serve the fast-growing pharmaceutical industry, as evident from the accredited GLP compliance laboratory and GMP QC testing laboratory working on both small molecule drugs and protein drugs. The laboratory is equipped with state-of-the-art analytical instruments for sensitive and high throughput drug quantification in various biological matrices. A great variety of comprehensive methods have been developed and validated for contract research, as well as SOPs been established and applied to ensure the result been delivered to its highest quality.

明生生物は台湾で初めてのCRO (Contract Research Organization) 企業で、顧客に臨床試験サービスと分析サービスを提供しています。30年以上の経験を積み重ね、医薬品の開発を臨床前試験から臨床研究段階に進展させます。私たちは主に化学薬品とタンパク質の新薬開発に焦点を当て、薬物動態研究、初期のヒト臨床試験、生物製剤の特性分析、および生物学的同等性試験を提供しています。また、明生生物は優れた品質管理システムを持ち、豊富な医薬品開発の経験を積んでおり、高度な専門知識とサービスへの情熱を備え、カスタマイズされたサービスソリューションを提供しています。

#### Highlights of the Year:

Clinical Trial and Laboratory Services



培力藥品工業股份有限公司  
Pei Li Pharmaceutical Industrial Co.,Ltd.

www.peili.com.tw

Services: CMO, CDMO, R&D, In/Out Licensing

- Therapeutic Area:
- 1. Hormones, Obstetrics & Gynecology
  - 2. Genitourinary
  - 3. Metabolic Diseases
  - 4. Gastroenterology (GI)
  - 5. Oncology (Non-Cytotoxic)

- Dosage Forms:
- 1. Tablets
  - 2. Capsules
  - 3. Soft Capsules
  - 4. Ointment

#### Brief Introduction:

Pei Li was established in 1976, focusing on research and development of high barrier generic drugs and healthcare products. Our facility has been passed Japan PMDA and Taiwan PICs/GMP inspection. There are 6 products which have been approved in Japan. Among these products, three are hormone-related drugs and one is high potent soft capsules.

Pei Li's Specialty:

- 1. Specialize in developing and manufacturing soft gelatin capsule (soft gel) for poorly soluble compounds or highly potent active ingredients.
- 2. Specialize in developing and manufacturing highly potent pharmaceutical products. Meanwhile, Pei Li has a dedicated production facility for highly potent pharmaceutical products, which can prevent cross contamination between high potent products and general pharmaceutical products.

ペイリー薬品 (Pei Li) は1976年に設立され、ジェネリック医薬品およびヘルスケア製品の研究開発に焦点を当てています。弊社の施設は、日本のPMDAおよび台湾のPIC/S/GMP審査をパスしています。日本で承認された製品は6品目あります。この中には、ホルモン関連の医薬品が3品目あり、また高薬理活性成分を含むソフトカプセルが1品目あります。

ペイリー薬品の専門領域:

難溶性の化合物や高薬理活性成分に対応するソフトゼラチンカプセル (ソフトゲル) の開発および製造に特化しています。

高薬理活性医薬品の開発および製造に特化しています。同時に、ペイリーは高薬理活性成分を含む製品と、一般の医薬品との交差汚染を防ぐため、専用の製造施設を有しています。

#### Highlights of the Year:

- 1. Soft Gelatin-Capsules
- 2. Hormone Related Products



Mithra

培力藥品  
PeiLi Pharm



王子製薬股份有限公司  
Prince Pharmaceutical Co., Ltd.


www.prince-pharm.com.tw

Services: CMO, CDMO, R&D

Product Type:  
1. APIs  
2. Dietary Supplement



王子製薬股份有限公司  
Prince Pharmaceutical Co., Ltd.



#### Brief Introduction:

Prince Pharmaceutical Co., Ltd. has been established in 1962. Now, we focus on two business scopes. One is APIs, the other one is Dietary Supplements.

With over 50-year experience, we are one of the world's leading producers of vitamin B1 derivatives active pharmaceutical ingredients, which has been successfully supplied to Taiwan, Japan and Europe etc. Not only APIs of vitamin B1 derivatives, we also developed numbers of APIs such as Ufenamate, Tulobuterol, Aldioxa, Felbinac etc., many new projects of R&D are ongoing.

Furthermore, in order to expand capacity of plant and fulfill new business, our new APIs plant which is located in Yulin started operation in 2020.

In business of Dietary Supplements, we provide professional OEM/ODM service for well-known domestic and foreign customers.

For years, Prince Pharma has always insisted on our corporate belief of "A company that improves people's health by providing the best pharmaceuticals" and treated customer satisfaction as our highest priority.

王子製薬株式会社は1962年に設立されました。現在、当社は2つの事業領域に焦点を当てています。1つはAPI (有効成分)、もう1つは健康補助食品です。

50年以上の経験を有する当社は、世界有数のビタミンB1誘導体の製造業者の一つであり、これは台湾、日本、ヨーロッパなどに輸出されています。ビタミンB1誘導体のAPIだけでなく、Ufenamate、Tulobuterol、Aldioxa、Felbinacなど、数々の新しいAPIも開発しており、多くの研究開発プロジェクトが進行中です。

さらに、工場の能力を拡張し新しいビジネスに対応するために、2020年に稼働を開始した新しいAPIプラントが台湾・雲林県にあります。

健康補助食品の事業では、国内外の有名な顧客に対してOEM / ODMサービスを提供しています。

長年にわたり、王子製薬は常に「最高の医薬品を提供することで人々の健康を改善する企業」の信念を堅持し、顧客満足を最優先事項としています。

#### Highlights of the Year:

Fursultiamine-GMP Certificate

松瑞製薬股份有限公司  
Savior Lifetec Corporation

www.saviorlifetec.com.tw/en

Services: CMO, CDMO, CRO

Therapeutic Area:  
Antibiotic

Dosage Forms:  
Injectables

SLC  
PHARMA



#### Brief Introduction:

Savior Lifetec Corporation is a specialty injectable company based in Chunan, Taiwan. Our state-of-the-art facilities are vertically integrated, capable of producing sterile API and finished dosage formulations. Our facilities comply with the highest quality standards, having passed inspections by authorities from the US, EU, and Japan. SLC also has dedicated state-of-the-art GLP compliant R&D centers for API research and pharmaceutical research.

SLC's expertise in sterile crystallization and the aseptic processing of sterile powder serves as the foundation for product innovation.


Savior Lifetec Corporation (SLC) は、台湾苗栗県竹南町に拠点を置く特殊注射剤企業です。当社の最先端の施設は垂直統合されており、無菌原薬および製剤を生産する能力を備えています。弊社の設備は、米国、EU、および日本の薬事行政機関の審査をパスし、最高の品質基準に準拠しています。SLCには、API研究および製薬研究のためのGLP (Good Laboratory Practice) に対応した専門の最新鋭の研究開発センターもあります。


SLCの無菌結晶および無菌粉末の無菌処理に関する専門知識は、製品革新の基礎となっています。


#### Highlights of the Year:


1. Meropenem-Injectable-Launched
2. Ertapenem-Injectable-Launched




 杏輝藥品工業股份有限公司  
Sinphar Pharmaceutical Co., Ltd.

 www.sinphar.com.tw/

 Services: CMO, CDMO

 Therapeutic Area:  
1. Oncology 4. Gastrointestinal  
2. Hormone 5. External Use  
3. Ophthalmology

 Dosage Forms:  
1. Tablets 4. Solutions  
2. Capsules/Soft Capsules 5. Lyophilizate  
3. Injections

#### Brief Introduction:

Sinphar Pharmaceutical is a publicly traded company and a certified PIC/s GMP, ISO 9001, ISO 14001, ISO 22000, Food GMP and OHSAS 18001 pharmaceutical company in Taiwan.

"Safety, stability, validity, and convenience" are elements we constantly emphasize in our quality policy. Holding both strong R&D capability and stringent control over product quality, Sinphar has fully demonstrated trustworthy techniques and skills in food products, cosmetics, pharmaceuticals, and anti-cancer drugs in both own brands and contract manufacturing services.


Following years of development, Sinphar has gradually consolidated its R&D capabilities in cancer drugs and new drugs, allowing us to build Taiwan's first pharmaceutical R&D center that specializes in isolated, automated production of cancer injections and cytotoxic agents. For sales distribution channel, Sinphar was the first to establish Sinphar Counter, a shop-in-shop business model, in 1997. Now there are approximately 1300 branches across Taiwan, making Sinphar Counter the largest specialized pharmacy in Taiwan.


杏輝藥品は台湾の上場企業として、品質に関するPIC/S GMP、ISO9001、ISO17025、ISO14001、ISO22000、ISO45001、HALALおよび自発的に化粧品の優良製造を実践するGMPなどの多くの認証を受けています。「安全、安定、効果的、利便性」は杏輝が品質管理の方針として常に堅持してきたものであり、専門的な研究開発技術能力と製品品質の厳格な管理を組み合わせることで、国内外の有名な大手メーカーからの受託生産を行っています。


#### Highlights of the Year:


Lyophilization Products-Under Development




 生達化學製藥股份有限公司  
Standard Chem. & Pharm. Co., Ltd.

 www.standard.com.tw/

 Services: CMO, CDMO, R&D

 Therapeutic Area:  
1. Cardiovascular 4. Anti-Inflammatory  
2. Digestive 5. CNS  
3. Diabetes 6. Urology  
7. Respiratory

 Dosage Forms:  
Oral solids: IR, SR, OROS, DR, ODT, MUPS

#### Brief Introduction:

Established in 1967, Standard Chem. & Pharm. Co., Ltd (SCP) is a renowned global pharmaceutical manufacturer with a strong international presence. We have gained widespread recognition for our commitment to excellence in the industry. Guided by our corporate philosophy of "Sincerity, Honesty, Excellence, and Innovation," SCP has emerged as a leading pharmaceutical company in Taiwan.

As the flagship company of the Standard Group, SCP offers a comprehensive product portfolio that encompasses Pharmaceuticals, APIs, and Health Supplements. This diverse range of offerings positions us as a fully integrated company, capable of meeting diverse market demands.

At SCP, we consistently surpass quality standards, consistently exceeding expectations. Our state-of-the-art manufacturing facilities have received numerous accolades from prestigious domestic and international regulatory agencies, including T-FDA, US-FDA, PMDA, KFDA, and TGA, among others. These recognitions serve as a testament to our unwavering commitment to maintaining the highest quality in our products.

Furthermore, SCP takes pride in our strong focus on customer satisfaction. We constantly strive to surpass partner expectations, ensuring mutually beneficial collaborations and solidifying our position as a leader in the Taiwanese pharmaceutical industry. By partnering with SCP, clients are guaranteed success in both the Taiwanese and international markets.

With decades of expertise and an unwavering commitment to innovation and excellence, Standard Chem. & Pharm. Co., Ltd stands as a trusted partner for pharmaceutical needs, driving progress in the global healthcare industry.

生達化学製薬は、台湾を代表するジェネリック医薬品メーカーです。積極的に研究開発に投資し、高品質な薬を地元および世界中の患者に提供しています。

生達のポートフォリオは、あらゆる治療領域を網羅しています。さらに、グローバル企業と連携し、ビジネスを強化し、業界での認知度を高めています。

#### Highlights of the Year:

1. Guanfacine SR-Tab-Pre-BE Trial Completed
2. Enzalutamide-Tab-Pre-BE Trial Completed





祥翊製藥股份有限公司  
Sunny Pharmtech Inc.

www.sunnypharmtech.com/

Sunny  
Pharmtech

Services: CMO, CDMO, R&D

Therapeutic Area:  
1. Oncology  
2. Genitourinary  
3. Vitamins

Dosage Forms:  
1. General and High Potent OSD  
2. High Potent Injection (Vial/Sterile Powder Fill)  
3. High Potent Softgel



#### Brief Introduction:

By integrating innovative talents, cutting edge technologies, and FDA- & TFDA- inspected facility for drug substance and drug products, Sunny provides quality generics and CDMO/CMO services to global markets through worldwide partnership.

SunnyPharmtechは、革新的な人材、最先端の技術、FDA および TFDA による原薬および医薬品の検査施設を統合することにより、世界規模のパートナーシップを通じて高品質のジェネリック医薬品および CDMO/CMO サービスを世界市場に提供しています。

#### Highlights of the Year:

1. Cyclophosphamide-Injection, 500mg, 1 g, 2 g,
2. Powder for Solution-Launched in US, Seek for EX-US Collaboration

瑞士藥廠股份有限公司  
Swiss Pharmaceutical Co., Ltd.

www.swisspharm.com.tw

SWISS

Services: CMO, CDMO, R&D

Therapeutic Area:  
1. Psychiatry and Central Nervous System  
2. Metabolism System  
3. Circulatory and Cardio-Vascular System  
4. Anti-Infectious  
5. Anti-Inflammatory and Analgesic

Dosage Forms:  
1. Solid Dosage Forms: (US FDA)  
• Tablets, Granules, Capsules  
2. Semi-Solid Dosage Forms:  
• Ointment, Cream, Gel  
3. Liquid Dosage Forms:  
• Solution, Syrup  
4. Sterile Dosage Forms:  
• Injection Solution (Aseptic Process and Terminal Sterilization)  
5. Cephalosporin Products (Dedicated Facility):  
• Powder for Injection  
• Capsules and Granules



#### Brief Introduction:

Swiss Pharmaceutical was established in 1966 with the mission of developing and manufacturing quality pharmaceutical generics products. Throughout the past 55 years, Swiss operates with the mindset of continuous improvement to pursuit this mission. Headquartered in Tainan City and currently has 450+ outstanding staffs and annual revenue of USD 38 million in FY2023.

Swiss has gone through several transformation. The most recent key transformation started in 2007, when we acquired a 40,000 m<sup>2</sup> property to build our new facility. The facility was PIC/S GMP certified in 2012 and has opened various of opportunities which eventually lead to our first US ANDA CMO project. Swiss was inspected in 2017 and 2019 by the US FDA.

For next step, we will continue to sharpen our skill in both product development and manufacturing and are seeking for partners who has the same mindset to form strategic alliance.

瑞士製薬は1966年に設立され、高い品質のジェネリック医薬品の開発と製造を使命としています。過去55年間、瑞士製薬はこの使命を追求するために継続的な改善の精神で運営されてきました。台南市に本社を置き、現在は450人以上の優れたスタッフと2023年度の年間収益が3,800万ドルあります。

瑞士製薬はいくつかの変革を経ています。最近の主要な変革は2007年に始まり、私たちの新しい施設を建設するために40,000平方メートルの土地を取得しました。その施設は2012年にPIC/S GMP認証を受け、最終的には私たちの初の米国ANDA CMOプロジェクトに繋がる様々な機会を提供しました。瑞士製薬は2017年と2019年に米国FDAによる査察を受けました。


次のステップでは、製品開発と製造の両方でスキルを磨き続け、同じ志向を持つパートナーと戦略的な提携を形成することを目指しています。


#### Highlights of the Year:


Pipeline:


- |                                       |                                |
|---------------------------------------|--------------------------------|
| 1. Prednisolone-Tablet (TW, US)       | 4. Colestipol-Tablet (US)      |
| 2. Ropinirole ER-Tablet (Requip XL)   | 5. Acotiamide-Tablet (Acofide) |
| 3. Tofacitinib XR-Tablet (Xeljanz XR) | 6. Elagolix-Tablet (Orillisa)  |




 健喬信元醫藥生技股份有限公司  
Synmosa Biopharma Corporation

 [www.synmosa.com.tw/EN/home/Default.asp](http://www.synmosa.com.tw/EN/home/Default.asp)

 Services: CDMO, R&D

 Therapeutic Area:  
1. Cardiovascular 4. Urology  
2. Respiratory 5. CNS  
3. Hormones

 Dosage Forms:  
1. Metered-Dose Inhaler (MDI)  
2. Nasal Sprays  
3. Oral Solid Dosage Forms (Cap, FCT, ODT, SCT, Hormone Tablets, Granules, Effervescent Tablet)  
4. Solution and Even Ointment

#### Brief Introduction:

Synmosa Biopharma Corporation, a listed company in Taiwan OTC stock market (TW.4114), was founded in 1980. We develop sustainable business ranging from R&D, manufacturing, contract manufacturing as well as sales and distribution for both pharmaceuticals and health supplements.

Through constant mergers and acquisitions of potential domestic candidates, we have built a series of PIC/s manufacturing plants that specialized in the manufacturing of metered-dose inhaler (MDI), hormone preparations, nasal sprays, effervescent tablet, granules and even ointment, shaping us into the leading pharmaceutical company in various therapeutic areas of expertise such as cardiovascular, respiratory, hormones, urology, oncology, and CNS. Until today, we are still continuously expanding and putting more and more efforts in developing innovative medications and brand-name drugs.

As for global business development, we show direct presence in Hong Kong as well as Singapore, Philippines where we allocated our own competent sales and marketing team; whereas for Northeast Asia and Southeast Asia market we have a long-established and stable collaborative business relationship with local partners. We believe in improving the quality of lives of those in need with the highest standard of pharmaceutical manufacturing technology as we move towards our vision of becoming the foremost biopharmaceutical corporation in Asia.

Synmosa(シンモサ) Biopharma Corporation は、台湾株式市場 (TW.4114) の上場企業で、1980年に設立されました。当社は、医薬品と健康補助食品の研究開発、製造、受託製造、販売および台湾流通に至るビジネスを展開しております。


自社成長、工場買収、パートナー提携戦略を通じて、当社は五つPIC/s 製造工場を持ちしており、専門技術を用い、定量吸入器 (MDI)、ホルモン製剤、点鼻薬、発泡錠剤、顆粒、さらには軟膏も開発・製造を行っております。また、当社は、循環器科、呼吸器科、女性ホルモン、泌尿器科、腫瘍学、中枢神経系などのさまざまな治療専門分野における大手製薬会社に成長しています。継続的に拡大を続け、革新的な新薬医薬品の導入や後発医薬品の開発にますます力を入れております。


グローバルな事業展開に関しては、当社は香港、シンガポール、フィリピンで直接に拠点を置き、有能な販売およびマーケティングチームを独自に配置しています。一方、日韓および東南アジア市場についても現地パートナーと長年にわたって確立した安定した協力的なビジネス関係を築いております。私たちは、アジアで最も優れた医薬品企業になれるように最高水準の医薬品製造技術によって、困っている人々の生活の質を向上させることができると信じております。


#### Highlights of the Year:


Dufanas(Azelastine HCL+Fluticasone Propionate)-Compound Nasal Spray




 生泰合成工業股份有限公司  
Syn-Tech Chem.& Pharm. Co., Ltd.

 [www.syn-tech.tw/](http://www.syn-tech.tw/)

 Services: Manufacture APIs, Sale and Import/Export, CMO, R&D.

 Therapeutic Area:  
1. Cardiovascular 4. Psychiatry  
2. Immunology 5. Respiratory  
3. Metabolic Diseases

 Product Type:  
APIs(Powder, Liquid)



#### Brief Introduction:

Since 1982, Syn-Tech has been started in the API production industry, earning trust from major multinational companies. Recognized by authorities like the Taiwan FDA, US FDA, PMDA Japan, EDQM Europe, Australia and others, our commitment to quality and global standards is unwavering.

Beyond quality, we prioritize health, hygiene, environmental issues, and social responsibilities through PICs GMP, ISO & OHSAS systems, and ESG principles. Our mission is to serve customers with dedication, ensuring safety and delivering high-quality APIs—a commitment ingrained in our nearly 40-year journey. As we evolve, Syn-Tech remains dedicated to contributing to the pharmaceutical industry's progress through ethical and sustainable practices.

1982年以来、弊社は原薬製造業界に参入し、大手企業から信頼を得ていて、TFDA、USFDA、PMDA、EDQM、Australiaなど当局からの査察も通過しており、品質に対する当社のコミットメントは揺るぎません。

他にPICsGMP、ISO、OHSAS、ESGを通じて、健康、衛生、環境など社会的責任を優先しています。私たちの使命は安全を確保し、高品質のAPIをお届けすること。

#### Highlights of the Year:

Guanfacine Hydrochloride-PV Stage Completed, Samples are available



信東生技股份有限公司  
Taiwan Biotech Co., Ltd.

www.taiwanbiotech.com.tw

Services: CMO, CDMO, R&D

Therapeutic Area:

1. Ophthalmology
2. Respiratory
3. Cardiovascular
4. Central Nervous System
5. Antimicrobial Agents

Dosage Forms:

1. Oral Solids
2. Injections
3. Inhalation Solution
4. Eye Drops
5. TDDS Patch

#### Brief Introduction:

Taiwan Biotech is a PIC/S GMP pharmaceutical manufacturer in Taiwan. Established in 1945, we have more than 1,000 staffs now and have devoted ourselves to develop and supply the superior generic drugs.

The products we offer cover a wide range of therapeutic categories focus on cardiovascular, CNS, diabetic, respiratory and eye care drugs. With the complete production capability, we provide the oral solids, injections, inhalation solution, eye drops, TDDS patch, creams and ointments as a one-stop shop to our customers.

Taiwan Biotech is specialized in the manufacture of aseptic Blow-Seal-Fill products, including the unit dose eye drops, contact lens care solution, inhalation solution, injection, oral solution and wound cleaning solution. Filling volume is available from 0.2ml to 20ml. With its profession in this field, Taiwan Biotech is a CMO partner for the top OTC and generic companies for over 20 years.

We provide the professional CMO/CDMO services and welcome the out-licensing and in-licensing business opportunities.

台湾バイオテックは、1945年に設立された台湾の医薬品メーカーである、1,000人以上のスタッフを擁し、ジェネリック医薬品の開発と供給に注力しています。

様々な製品と剤型を製造しており、特に無菌充填であるBFS製品を製造する技術を持っており、BFS製品の容量は0.2mlから20mlまでがあり、単回使用の目薬、コンタクトレンズ用洗浄液、吸入液、注射剤、経口液や創傷洗浄液を製造することが可能です。

製造工場については日本厚生労働省に認定され医薬品及び医薬部外品における、外国製造業者認定工場として、承認されました。PMDAより実地GMP適合性調査を受けられました。

CMOパートナーとして20年以上の実績があり、CMO/CDMOサービスをご提供させて頂きます、ライセンスアウトおよびライセンスインのビジネスチャンスを探求しております。

#### Highlights of the Year:

Sodium Hyaluronate-Eye Drops-Under License Application



大協生化科技股份有限公司  
Taiwan Tasheh Biotech Co.,Ltd

www.shengzou.com

Services: Medical Supplies

Product Type:  
Pharmaceutical Packaging



#### Brief Introduction:

With over 50 years of material science and formulation experiences, SZ has delivered numerous advanced formulations/technologies and in turn provided uncompromised quality products in pharmaceutical packaging to customers. SZ's capabilities are uniquely situated to providing customer-suited specifications designed to go above and beyond the current standards commonly adopted by the industry. When it comes to quality, customer service, and continuous improvement, long-establish core competencies at SZ, we are proudly to be one of the leading manufactures in the industry. Our container closure are designed to provide superior long term stability and purity of drugs contained within, ultimately ensuring safety to patients, all backed by SZ's guaranteed solutions.

50年を超える材料科学と製剤の経験を持つSZは、数多くの高度な製剤/技術を提供し、医薬品包装における妥協のない高品質の製品を顧客に提供してきました。SZの機能は、業界で一般的に採用されている現在の標準を超えるように設計された、顧客に適した仕様を提供するという独自の立場にあります。品質、顧客サービス、継続的改善に関しては、SZが長年確立してきたコアコンピテンシーとして、当社は業界をリードするメーカーの1つであることを誇りに思っています。当社の容器クロージャは、内部に含まれる薬剤の優れた長期安定性と純度を提供するように設計されており、最終的に患者の安全を確保します。これらはすべてSZの保証されたソリューションによって裏付けられています。

#### Highlights of the Year:

1. PTFE Silicone Free Prefilled Syringe 0.5ml, 1ml, 2.25ml, 3ml
2. Stacked Needle and Luer Lock

聯亞藥業股份有限公司  
UBI Pharma Inc.

www.ubi-pharma.com/en/

Services: CMO, CDMO, R&D, In/Out Licensing

Therapeutic Area:  
All Except High-Potency  
Cytotoxic, Sex Hormone

Dosage Forms:  
1. Injectables  
2. Lyophilisate  
3. Semi-Solid  
4. Tablet  
5. Capsule



Brief Introduction:

UBI Pharma Inc. (UBIP) is one of the leading pharmaceutical companies in Taiwan. UBIP specializes in developing and manufacturing high quality generics and fusion protein drugs, as well as providing contract development and manufacturing services to global clients.

Our facility is routinely inspected by TFDA, USFDA, and PMDA. We are capable of manufacturing finished dosage form of sterile (vial, ampoule and lyophilized) and non-sterile (tablet, capsule, liquid, powder, cream and ointment), and have been the contract manufacturer for multiple world renowned pharmaceutical companies for more than 20 years. We are also selected for manufacturing of government controlled drugs and COVID-19 vaccine.

UBIP is continuing seeking global partners for providing high-quality, affordable and innovative medicines to help patients lead healthier lives.

聯亞藥業は2014年に設立された台湾の大手製薬会社です。高品質のジェネリック医薬品と融合タンパク質医薬品の開発と製造に特化しており、グローバルな顧客に受託製造サービス、受託開発製造サービスを提供しており、台湾FDA、米国FDA、日本のPMDAによるPIC/S GMPの認証を受けております。

Highlights of the Year:

UB-851 Recombinant Human Erythropoietin(EPO)-BLA Submission

元宙化學製藥股份有限公司  
Yuanchou Pharma

yuanchou.com.tw

Services: CMO, CDMO

Therapeutic Area:  
1. Antibiotics 4. Gastrointestinal  
2. Diabetes 5. Supplement  
3. External Use

Dosage Forms:  
1. Tablets  
2. Capsules  
3. Granules  
4. Semi-Solid Dosage Forms  
5. Spray



Brief Introduction:

Yuanchou Pharma (YCP) was established in 1981. Obtained PIC/S certification in 2014. We focus on generic drug development and production.

Actively invest in new ingredients, new materials, new equipment, and new process to facilitate product development.

Develop new dosage forms to meet the therapeutic needs for various clinical drugs to reduce side effects and to benefit patients.

In 2023, we have sold:  
260,000,000 tablets and capsules, 17 tons of sachets, 13 tons of cream and ointment, & 4,000 liters of liquid dosage.

元宙製藥 (YCP) は1981年に設立され、2014年にPIC/S認証を取得しました。当社はジェネリック医薬品の開発と製造に焦点を当てています。

新しい成分、新しい材料、新しい機器、新しいプロセスへの積極的な投資を行い、製品開発を促進しています。

様々な臨床薬物の治療ニーズに応えるために新しい投与形態を開発し、副作用を減少させ患者に利益をもたらしています。

2023年には、以下の販売実績があります：  
2億6000万錠とカプセル、17トンの袋詰め製剤、13トンのクリームと軟膏、および4,000リットルの液体製剤。

Highlights of the Year:

Sunmuk-Granules- Ready to Launch







# Taiwan

Pharmaceutical Alliance

Taiwan Pharmaceutical Alliance

☎ +886-2-6625-1166

✉ BDD@pitdc.org.tw

🌐 <http://www.tpatw.org.tw>